Mitochondrial metabolism in hematopoietic stem cells requires functional FOXO3

Pauline Rimmelé1,†, Raymond Liang1,2,†, Carolina L Bigarella1,†, Fatih Kocabas3, Jingjing Xie3, Madhavika N Serasinghe4, Jerry Chipuk4,5, Hesham Sadek3,6, Cheng Cheng Zhang6 & Saghi Ghaffari1,2,5,7,8,*

Abstract

Hematopoietic stem cells (HSC) are primarily dormant but have the potential to become highly active on demand to reconstitute blood. This requires a swift metabolic switch from glycolysis to mitochondrial oxidative phosphorylation. Maintenance of low levels of reactive oxygen species (ROS), a by-product of mitochondrial metabolism, is also necessary for sustaining HSC dormancy. Little is known about mechanisms that integrate energy metabolism with hematopoietic stem cell homeostasis. Here, we identify the transcription factor FOXO3 as a new regulator of metabolic adaptation of HSC. ROS are elevated in Foxo3-/- HSC that are defective in their activity. We show that Foxo3-/- HSC are impaired in mitochondrial metabolism independent of ROS levels. These defects are associated with altered expression of mitochondrial/metabolic genes in Foxo3-/- hematopoietic stem and progenitor cells (HSPC). We further show that defects of Foxo3-/- HSC long-term repopulation activity are independent of ROS or mTOR signaling. Our results point to FOXO3 as a potential node that couples mitochondrial metabolism with HSC homeostasis. These findings have critical implications for mechanisms that promote malignant transformation and aging of blood stem and progenitor cells.

Keywords FOXO3; HSC; metabolism; mitochondria; ROS

Subject Categories Metabolism; Stem Cells

DOI 10.15252/embr.201439704 | Received 9 October 2014 | Revised 11 June 2015 | Accepted 15 June 2015

Introduction

Like all stem cells, hematopoietic stem cells (HSC) are characterized primarily by self-renewal and multipotency [1]. Blood stem cells in adults are largely dormant in the bone marrow (BM) hypoxic niches and divide extremely rarely [2–4]. Despite quiescence, however, a single HSC has the potential to reconstitute the entire hematopoiesis in response to damage or loss. This implies that blood stem cells have the ability to be efficiently activated and rapidly divide to regenerate hematopoietic tissue in a relatively short period of time. This intrinsic potential of HSC to reconstitute all blood cells in a mouse in which bone marrow is ablated is an exquisite measure of their activity [5]. The quiescence of blood stem cells and their self-renewal are highly coupled [1], making the tight balance between quiescence and proliferation of HSC key to the maintenance of the HSC pool throughout adult life. HSC must therefore be poised with plasticity to adapt metabolically to either quiescence or the highly active state.

HSC dormancy is maintained by low metabolic activity supplied by glycolytic metabolites in hypoxic niches [6,7]. In agreement with this, dormant HSC exhibit very low levels of reactive oxygen species (ROS) that are intimately tied to cellular metabolic activity [7–9]. Although oxygen radicals are mostly known for their deleterious properties, they also serve as signaling messengers that variably influence cell fate [10,11]. Dormant HSC are acutely sensitive to oxidative stress, a cellular state instigated by an imbalance between the generation and the detoxification of ROS [12–17]. In many cases, unbalanced accumulation of ROS mediates deficiencies of HSC function [12,18,19]; however, the impact of ROS on HSC activity when mitochondrial function is defective is less clear [20–26].

Mitochondria are the major site of ATP production through oxidative phosphorylation and constitute the metabolic center of the cell. During the process of oxidative phosphorylation, ROS are
produced as the by-product of mitochondrial respiration [11]. HSC contain relatively few and inactive mitochondria [7,27] consistent with their low levels of ROS. Recent evidence suggests that mitochondria have a key function in the maintenance of HSC quiescence and their potency to rapidly switch from dormancy to a metabolically active state [20,22–24,27–31] (and reviewed in [32]). mTOR signaling in particular has been implicated in HSC mitochondrial biogenesis [20]. Despite this importance, relatively little is known about the mechanisms that control mitochondria or the metabolic adaptation in HSC.

Among potential candidates that may regulate stem cell metabolism are homeostatic FOXO proteins [33]. Transcription factors FOXO (FOXO1, FOXO3, FOXO4, FOXO6 in mammals) are critical regulators of oxidative stress [34–39]. In addition, FOXOs are key regulators of some fundamental biological processes including cell cycle, apoptosis, and metabolism that by integrating various signals insure tissue homeostasis [30,33]. Notably, FOXOs are among the very few transcription factors that are essential for the maintenance of pluripotency/multipotency in several types of stem cells including adult hematopoietic and neural, and embryonic pluripotent stem cells [14–16,40–44] as well as both mouse and human leukemic stem cells [45–47]. FOXO3 is the principal FOXO required to maintain normal adult hematopoietic and leukemic stem cells [15,16,45–48]. In addition, genetic variation within FOXO3 gene is associated with human longevity [49]. These functions combined with other FOXO3 attributes including its key role in communicating mitochondrial–nuclear signals [50,51] and its potential function in HSC aging [15,17,48] make FOXO3 a suitable candidate for regulating HSC metabolism. Consistent with a potential metabolic function in HSC, FOXO3 is critical for the regulation of oxidative stress in HSC and hematopoietic progenitors; loss of FOXO3 results in elevated ROS associated with defective HSC activity [15–17], as well as ROS-mediated myeloproliferation in mice [41]. Whether FOXO3 is implicated in the mitochondrial regulation of HSC remains unexplored.

Here, we show that FOXO3 is critical for the regulation of mitochondrial respiration in HSC. We further show that the deficiency of Foxo3−/− HSC activity as measured by long-term competitive repopulation is not predominantly mediated by the enhanced levels of ROS or mTOR activation. In addition, we provide evidence that activation of mTOR signaling pathway mediates the abnormal mitochondrial function in the less primitive subset of Foxo3−/− mutant HSPC. Our combined results suggest that elevation of ROS is not solely due to the reduced expression of antioxidant enzymes [34] in Foxo3−/− HSC in vivo [14–16], rather elevated ROS is associated with, and may indicate, an underlying unhealthy mitochondrial state [52] in Foxo3−/− HSC. These findings are likely to have important implications for mechanisms that control hematopoietic stem cell homeostasis and aging as well as leukemic stem cell activity.

## Results

### Loss of FOXO3 represses mitochondrial metabolism in HSC

To address whether FOXO3 regulation of HSC metabolism is restricted to controlling ROS levels or is also implicated in a more global control of energy homeostasis, we investigated the status of mitochondrial function. ROS including mitochondrial superoxide are increased in Foxo3 mutant Lin−Sca−1−cKit− (LSK) cells, a population enriched for hematopoietic stem and progenitor cells (HSPC) that comprise < 0.05% of bone marrow (Fig EV1A and B) [15,16]. To further address mitochondrial function, we measured the levels of ATP (adenosine triphosphate) that is generated mainly through glycolysis and oxidative phosphorylation in hematopoietic stem cells [7,32]. Blood stem cells are accessed and isolated by flow cytometry using a combination of cell surface markers to deplete mature cells (Lin−, lineage negative), and enrich for a highly pure population of primitive cells. In our studies, we have used long-term HSC (LT-HSC) (CD34−Flk2−LSK or CD150−CD48−LSK) that are highly quiescent, constitute < 0.01% of total BM, and have the ability to reconstitute blood in a lethally irradiated mouse for at least 4 months [53]. With lineage specification, HSC generate progenitors with more restricted activity and lineage potential. Short-term HSC (ST-HSC) with more limited reconstitution capacity which does not surpass 2 months generate multipotent primitive hematopoietic progenitors (MPP) isolated in Lin−cKit+ Sca1− (c-Kit−) cells. These progenitor cells have also been included in our experiments.

Wild-type and Foxo3−/− LT-HSC were freshly isolated from the bone marrow and subjected to ATP bioluminescence assay [7]. To our surprise, ATP was depleted by almost 50% in Foxo3 mutant LT-HSC as compared to controls (Fig 1A). Oxygen consumption that is a major indicator of oxidative phosphorylation was also markedly reduced (almost by 50%) in Foxo3 mutant HSC as analyzed by an Oxygen Biosensor (Fig 1B). Lower rates of mitochondrial respiration may reflect lower energy requirements. That is unlikely since Foxo3 mutant HSC in contrast to their wild-type counterparts have exited the quiescence state and are likely subject to higher energy demand [15,16]. Alternatively, lower respiration rates may indicate that despite loss of quiescence, Foxo3 mutant HSC increase glycolysis for energy production instead of increasing oxidative phosphorylation. In agreement with this, using gas chromatography–mass spectrometry we found increased 13C lactate production in the Foxo3 mutant LT-HSC, suggesting the glycolytic flux was enhanced in these cells (Fig 1C). Collectively, these results indicated (Fig 1A–C) a shift in the ATP production from oxidative phosphorylation in mitochondria to glycolysis in the cytosol of Foxo3 mutant HSC. Glycolysis is a relatively inefficient means for generating ATP [54]. Nonetheless, the increased glycolysis associated with ATP depletion by half and impaired mitochondrial respiration in Foxo3 mutant HSC suggests that oxidative phosphorylation is compromised. These results were highly unexpected as HSC use glycolysis as their main source of energy [7,9,28,55]. Mutations that cause HSC loss of quiescence associated with increased ROS as observed in Foxo3−/− HSC are often associated with decreased glycolysis and increased oxidative phosphorylation that is the major alternative source of energy to glycolysis in HSC [18–20].
Figure 1. Mitochondrial dysfunction in Foxo3−/− HSC.

A–C Mitochondrial parameters as ATP level (A), oxygen consumption (B), and lactate production (C) were measured in WT and Foxo3−/− LT-HSC (LSKCD48+Flk2−) (n = 10 mice in each group), and experiments were performed in triplicate.

D–F Mitochondrial mass (D) and membrane potential (E, F) were measured in freshly isolated primitive hematopoietic stem and progenitor cells. (D) One representative FACS plot of the mitochondrial mass measured by the geometric mean fluorescence intensity of MitoTracker Green of 2 (LT-HSC, LSKCD48+CD150−) or 3 (LSK and c-Kit+) independent experiments (n = 3 mice per genotype) is shown: LT-HSC, P = 0.324; LSK, P = 0.021; and c-Kit+, P = 0.092. (E) One representative FACS plot of the mitochondria membrane potential measured by the geometric mean fluorescence intensity of 1,1’-3,3’-3,3’-hexamethylindodicarbo-cyanine iodide [DiIC1(5)] of 2 (LT-HSC, LSKCD48+CD150−) or 3 (LSK and c-Kit+) independent experiments (n = 3 mice per genotype) is shown: LT-HSC, P = 0.046; LSK, P = 0.042; and c-Kit+, P = 0.478. (F) Mitochondria membrane potential was also measured using 5,5’6,6’-tetrachloro-1,1’3,3’-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) probe by flow cytometry. Monomeric JC-1 has a green fluorescent emission spectrum while its aggregated form has a red fluorescent emission spectrum. As JC-1 probe accumulates, its aggregates and shifts fluorescent color. Representative FACS plots of JC-1 red and green fluorescence and relative ΔΨm measured by the red/green fluorescence ratio are shown for each population (n = 3 mice per genotype for LT-HSC and n = 6 mice per genotype for LSK and c-Kit+ cells).

G Histogram (top) and quantification (bottom) of TMRE fluorescence intensity comparing mitochondrial membrane potential between WT and Foxo3−/− LT-HSC. TMRE fluorescence normalized to WT TMRE levels in LT-HSC (n = 3 mice per group).

Data information: All data are expressed as mean ± SEM (Student’s t-test, *P < 0.05).
generated by the respiratory chain drives ATP synthesis [56], and given the reduced mitochondrial respiration and ATP levels in Foxo3 mutant HSC, we suspected the mitochondrial membrane potential would be decreased. Unexpectedly however, the mitochondrial membrane potential was increased in Foxo3\(^{-/-}\) LT-HSC and LSK according to DiIC1(5) (Fig 1E), a probe that is actively transported into mitochondria in a mitochondrial membrane potential (ΔΨ\(_{m}\))-dependent manner. To confirm these results, we used JC-1 probe combined with flow cytometry. As anticipated [7], mitochondrial membrane potential was increased with differentiation and maturation of wild-type HSC (Fig 1F, compare LT-HSC, to LSK to c-Kit\(^{-}\) cells). However, the conversion of green to red fluorescence was increased in Foxo3\(^{-/-}\) LT-HSC (1.5-fold), and LSK (fourfold) as compared to wild-type controls independently of any other mitochondrial parameter indicating enhanced mitochondrial membrane potential (Fig 1F). Increased mitochondrial membrane potential was specific to Foxo3\(^{-/-}\) primitive hematopoietic stem cell compartment as it was not detected in Foxo3\(^{-/-}\) c-Kit\(^{-}\) cells (Fig 1F). Treatment with CCCP (carbonyl cyanide 3-chlorophenylhydrazone), an inhibitor of oxidative phosphorylation (Fig EV1C and D), reduced significantly both DiIC1(5) and JC-1 signals confirming their specificity. To further validate these measurements and exclude any potential aberration [57], we also used TMRE (tetramethylrhodamine, ethyl ester) to label active mitochondria. TMRE is a positively charged dye that readily accumulates in active mitochondria in live cells [57]. As anticipated, TMRE loading of mitochondria detected increased and decreased mitochondrial membrane potential after oligomycin inhibition of ATP synthase and CCCP inhibition of oxidative phosphorylation, respectively (Fig EV1E). Using TMRE, we further confirmed that mitochondrial membrane potential is significantly increased in Foxo3\(^{-/-}\) LT-HSC relative to controls (Fig 1G).

These results were highly unanticipated as increased mitochondrial membrane potential in HSC is often associated with increased oxidative phosphorylation [7]. Loss of quiescence [15,16] associated with increased mitochondrial membrane potential, decreased ATP, and reduced mitochondrial respiration (Figs 1 and EV1) despite high levels of ROS underscore an abnormality of Foxo3\(^{-/-}\) HSC mitochondrial function. Consistent with this contention, mitochondria was hyper-fragmented and mitochondrial morphology compromised in Foxo3\(^{-/-}\) HSPC, suggesting that mitochondrial dynamics [58] might be altered (Fig EV2). Collectively, these findings (Figs 1A-G, EV1 and EV2) suggest that mitochondrial function is defective in Foxo3\(^{-/-}\) HSC compartment. Increased glycolysis associated with enhanced mitochondrial membrane potential might indicate compensatory mechanisms responding to ATP depletion in Foxo3\(^{-/-}\) HSC.

**Inhibition of ROS in vivo does not rescue Foxo3\(^{-/-}\) LT-HSC phenotype**

Impaired oxidative phosphorylation was unexpected in Foxo3 mutant HSC [15–17,59] as defective HSC associated with abnormal accumulation of ROS as observed in Foxo3 mutant HSC often indicates a switch from glycolysis in quiescent HSC to oxidative phosphorylation in activated HSC [12,18,28,29]. In light of these findings, we suspected that accumulated ROS might not cause HSC defects [15–17]. If true, we reasoned that decreasing ROS levels in vivo with a glutathione precursor N-acetyl-cysteine (NAC) would not rescue the defects of Foxo3 mutant HSC. Indeed, loss of Foxo3 [15–17] (or FOXO [59]) is associated with oxidative stress in HSC. Elevated ROS mediate the increased production of myeloid colony-forming unit-spleen (CFU-S) progenitors in triple Foxo1\(^{-/-}\); Foxo3\(^{-/-}\); Atm\(^{-/-}\) mice as well as the activation of p38 MAPK in Foxo3\(^{-/-}\) LT-HSC [15] and to variable degrees the defective production of myeloid progenitors in long-term culture of Foxo3\(^{-/-}\) long-term culture initiating cell (LTC-IC) in vitro [16,17], a population that overlaps with, but is not restricted to, long-term competitive multilineage repopulating cells in vivo [60]. However, the contribution of elevated ROS to the dysfunction of Foxo3 (or Foxo4) mutant long-term competitive repopulation of HSC in vivo remained unexplored [15–17,59]. To investigate this, wild-type and Foxo3\(^{-/-}\) mice were treated in vivo with NAC for 2 weeks (Fig 2A). The NAC regimen used was not toxic and did not significantly alter the BM cellularity in wild-type or Foxo3\(^{-/-}\) mice (Fig 2A).

As anticipated, NAC treatment normalized the levels of ROS in Foxo3\(^{-/-}\) but did not alter ROS in wild-type LSK cells (Fig 2B). However, inhibition of ROS in vivo did not modulate significantly the reduced numbers of Foxo3\(^{-/-}\) LSK cells (Fig 2C). Similarly, this regimen did not impact significantly the Foxo3\(^{-/-}\) LT-HSC numbers (Fig 2D). We next injected 100 highly purified (LSKCD48\(^{-}\)CD150\(^{+}\)) Foxo3-deficient HSC into lethally irradiated recipient mice along with 200,000 recipient bone marrow cells in an in vivo competitive repopulation assay (Fig 2E). As previously reported [16], Foxo3-null HSC were highly compromised in their long-term competitive multilineage reconstitution of lethally irradiated recipients. However, prior treatment of Foxo3-deficient mice with NAC in vivo did not improve the long-term competitive repopulation ability of isolated Foxo3\(^{-/-}\) HSC as compared to animals treated with vehicle control in transplanted lethally irradiated recipients (Fig 2E). Although ROS levels were reduced in HSPC at the time of transplantation as a result of the NAC regimen (Fig 2B), we wondered whether NAC treatment for a longer period of time would have a positive effect on the Foxo3\(^{-/-}\) HSC repopulation ability. Competitive repopulation capacity of isolated LT-HSC from mice treated with NAC or vehicle control for 4 weeks was assayed in lethally irradiated mice as in Fig 2A. We confirmed that NAC is effective in reducing protein oxidation in Foxo3\(^{-/-}\) bone marrow cells by analyzing protein carbonyl derivaties before and after NAC treatment (Fig EV3). The 4-week NAC regimen improved initially the ability of Foxo3\(^{-/-}\) HSC to repopulate recipient mice at 4 weeks post-transplantation, but this improvement was lost after 8 weeks and not observed at any later time point up to 16 weeks post-transplantation (Fig 2F). This NAC regimen clearly reduces ROS in transplanted LT-HSC (Fig EV4A). The effect of NAC was maintained during the entire transplantation as judged by ROS levels in CD45\(^{+}\) peripheral blood cells 16 weeks post-transplantation (Fig EV4B). Taken together, these results suggest that in contrast to Atm\(^{-/-}\) HSC where NAC treatment of only Atm\(^{-/-}\) (donor) mice improved significantly the output of Atm\(^{-/-}\) HSC function in transplanted irradiated hosts [12], reducing ROS levels of Foxo3\(^{-/-}\) HSC had minimal effect on their long-term competitive repopulation ability in transplanted animals (Fig 2F). A potential explanation for these results might be that to insure continuous normal ROS levels, NAC treatment of recipient in addition to donor mice may be required during the entire transplantation for full restoration of the competitive repopulation ability of donor mutant cells [12,18]. Restoration of repopulation under such conditions might
indicate potential additional effects of NAC on bone marrow micro-environment. Regardless, NAC treatment of both pre- and post-transplanted Foxo3−/− HSC did not improve significantly their repopulation ability beyond 4 weeks post-transplantation (Fig 2F).

Similarly, the positive effect of post-transplant NAC treatment of Foxo3−/− HSC recipients did not last beyond 8 weeks (Fig 2F). Thus, unlike Atm−/− [12] and Meis1−/− HSC [18] where reducing elevated ROS rescued their long-term repopulation abnormalities, normalizing ROS levels in vivo may not be sufficient to overcome Foxo3−/− HSC long-term repopulation defects.
Reducing ROS levels does not improve Foxo3<sup>−/−</sup> HSC mitochondrial dysfunction<sup>in vivo</sup>

As a chronic increase in ROS might impair mitochondrial function [61], we evaluated whether Foxo3<sup>−/−</sup>-HSC mitochondrial dysfunction was at least partially due to increased ROS. The <i>in vivo</i> NAC treatment did not revert the abnormal increased mitochondrial membrane potential in Foxo3<sup>−/−</sup>-LSK cells as measured by both DilC1(5) (Fig 3A) and JC-1 (Fig 3B) probes. In agreement with these results, TMRE levels of Foxo3<sup>−/−</sup>-LT-HSC or LSK cells (Figs 3C and EV4C) despite reduced ROS levels (Fig EV4A and D) were not reduced in response to NAC treatment, suggesting that the increased mitochondrial membrane potential of Foxo3<sup>−/−</sup>-HSC was not due to oxidative stress. Altogether, these results indicate that loss of FOXO3 impairs mitochondrial function independent of ROS in HSC.

In agreement with this, many genes implicated in the regulation of mitochondrial function, electron transfer chain, and/or metabolism, particularly glycolysis, were significantly deregulated in Foxo3<sup>−/−</sup>-HSPC (Fig 4). Among these genes, impaired expression of a master regulator of mitochondrial biogenesis peroxisome proliferator-activated receptor-γ coactivator (Pgc) 1 was notable. Some of these genes that are potential direct targets of FOXO3 including isocitrate dehydrogenase 1 (<i>Idh1</i>) and Idh2 genes [62,63] were specifically modulated in Foxo3<sup>−/−</sup>-HSPC (LSK cells), but not in more committed Foxo3<sup>−/−</sup>-c-Kit<sup>+</sup> hematopoietic progenitor cells. One of the most remarkable impacts among the genes surveyed was on Atpif1, the inhibitor of mitochondrial F1F0-ATPase that limits the ATP depletion. Atpif1 expression was reduced by over 60% (Fig 4A). Reduced expression of Atpif1 maintains mitochondrial membrane potential to protect cells with severe deficiencies in electron transfer chain from apoptosis [64]. It is noteworthy in this context that mitochondrial membrane potential is elevated in Foxo3<sup>−/−</sup>-HSC (Fig 1E–G), and despite high ROS, these cells do not exhibit increased apoptosis [15].

Thus, loss of Foxo3<sup>−/−</sup>-HSC long-term competitive repopulation is associated with impaired mitochondrial metabolism, but not mediated by ROS. These combined findings raise the possibility that compromised Foxo3<sup>−/−</sup>-HSC mitochondria may be implicated in defects of Foxo3<sup>−/−</sup>-LT-HSC activity.

Inhibition of mTOR signaling improves ROS levels but does not ameliorate Foxo3<sup>−/−</sup>-LT-HSC function <i>in vivo</i>

The mammalian target of rapamycin (mTOR) is critical for the regulation of mitochondrial biogenesis including in HSC [20,65,66].
mTOR signaling senses nutrients availability and is a key regulator of cell growth. mTOR protein kinase exists in two distinct core complexes, mTOR complex I and II (mTORC1 and mTORC2, respectively) which differ in their regulation and functions as well as in their sensitivity to rapamycin [67]. As an interplay between mTORC1 and FOXO3 is implicated in the myeloid progenitor homeostasis [41,62] and the glycolytic enzyme regulation [62,68], we investigated whether mTORC1 signaling was involved in the defective mitochondrial function in Foxo3−/− HSC. Interestingly, loss of FOXO3 increased the fraction of HSPC expressing the phosphorylated form of S6 that is a reliable indicator of mTORC1 activity [67] as measured by flow cytometry (Fig 5A). These results suggest that as in myeloid progenitors [41,62], FOXO3 might inhibit mTOR signaling in primitive HSPC. To investigate this, we evaluated the impact of pharmacological inhibition of mTORC1 signaling on the phenotype of Foxo3−/− HSC. Wild-type and Foxo3−/− mice were treated in vivo for 2 weeks with rapamycin [67] that is a specific inhibitor of mTORC1 (Fig 5A). As anticipated, this treatment normalized the levels of S6K1 target ribosomal protein S6 phosphorylation (Fig 5A, upper panel) and reduced significantly the frequency of Foxo3−/− LSK cells positive for pS6 to levels similar to wild-type control cells (Fig 5A, lower panel), without any significant impact on wild-type control cells. Treatment with rapamycin in vivo did not modulate the mitochondrial membrane potential as measured by either DilC1(5) (Fig 5B) or JC-1 (Fig 5C) probes in WT LSK cells (Fig 5B and C). Notably however, this treatment mitigated the increased ∆Ψm levels in Foxo3−/− LSK cells (Fig 5B and C). In addition, the in vivo treatment with rapamycin normalized ROS levels in freshly isolated Foxo3−/− LSK (Fig 5D) cells as has been previously observed in Foxo3−/− committed myeloid progenitors [41]. These results suggest that activation of mTOR signaling mediates the abnormalities of mitochondrial membrane potential in Foxo3−/− HSPC in vivo.

We next investigated whether activation of mTOR signaling contributes to Foxo3−/− HSC activity defects. As anticipated, the 2-week in vivo treatment with rapamycin did not impact the BM cellularity (Fig 6A). Interestingly, while rapamycin treatment did not modulate significantly the HSC pool in wild-type mice (Fig 6B-D), this regimen rescued the total numbers (Fig 6B) and the frequency of Foxo3−/− LSK cells (Fig 6C). In contrast to these effects, the rapamycin regimen did not alter the numbers (Fig 6D) or the frequency (not shown) of Foxo3−/− LT-HSC in the bone marrow (Fig 6D). This regimen was sufficient to inhibit mTOR signaling (Fig 5A); furthermore, similar rapamycin regimen had positive effects on Lkb1−/− LT-HSC numbers [22–24], together raising the possibility that mTOR activation impacts specifically Foxo3−/− HSPC subset that excludes cells with long-term competitive repopulation competence. In agreement with this interpretation, rapamycin-treated Foxo3−/− HSC repopulated recipients only up to 8 weeks post-transplantation (Fig 6E). However, rapamycin- and vehicle control-treated Foxo3−/− HSC were similarly defective in their ability to competitively reconstitute hematopoiesis at 12 and 16 weeks post-transplantation in irradiated hosts (Fig 6E), suggesting that rapamycin did not have a major impact on Foxo3−/− LT-HSC competitive repopulation ability. Relative to their wild-type counterparts, a significant fraction of Foxo3-defective HSPC exit quiescence (G0) [15,16] (Fig 6F). In agreement with the lack of effect on Foxo3−/− HSC long-term repopulation, the rapamycin treatment modulated only marginally the Foxo3−/− HSPC cycling status or the quiescent (G0) fraction of Foxo3−/− HSPC as measured by Ki-67+ proliferating cells and DAPI staining (Fig 6F). Unexpectedly however, we observed that rapamycin-treated wild-type HSC exited quiescence state (Fig 6F).

Altogether, these results suggested that short-term but not long-term Foxo3−/− HSC defects were mediated by the activation of mTOR signaling.
Discussion

FOXO3 is critical for mitochondrial metabolism in HSC

Here, we showed that FOXO3 is critical for mitochondrial respiration in LT-HSC independently of its regulation of mTOR activity or ROS levels. Although mitochondria are relatively inactive in HSC, mitochondrial function is required for the proper maintenance of blood stem cell activity [21–24]. Elevation of ROS in defective mutant HSC associated with loss of quiescence often signals a switch to mitochondrial oxidative phosphorylation [18–20]. Foxo3−/− HSC loss of quiescence [15–17], however, was paradoxically associated with increased glycolysis, elevated ROS and significant reduction of oxidative phosphorylation, abnormalities of mitochondrial membrane potential and mass (Figs 1 and 2) as well as aberrant expression of critical genes implicated in mitochondrial functions (Fig 4). In agreement with previous findings [7,27], our data support the notion that the regulation of mitochondria is distinct between hematopoietic stem and progenitor cells; furthermore, that FOXO3 is required for mitochondrial metabolism in LT-HSC (Figs 1–4). Given the expression and subcellular localization of FOXOs in Foxo3−/− HSPC [16] (R. Liang and S. Ghaffari, unpublished findings), it is unlikely that these observations are mediated through compensatory mechanisms by other FOXOs. These results raise the possibility that impaired mitochondrial metabolism may be implicated in abnormalities of Foxo3−/− HSC long-term repopulation.

These findings are in agreement with compromised Foxo3−/− HSPC function in generating colony-forming cells in vitro and with their delayed transition through the G2/M cell cycle phase [16,17]. They are also consistent with the lack of enhanced apoptosis in Foxo3−/− HSC despite elevated ROS [17] (C.L. Bigarella and S. Ghaffari, unpublished findings). These findings may also provide some explanation as to why FOXO3 is required for leukemic stem cell maintenance [45–47]. It will be interesting to see how mechanistically FOXO3 regulates mitochondrial metabolism and how this is integrated with the regulation of ROS and HSC activity.

The defective Foxo3−/− HSC activity is not mediated by elevated ROS in vivo

FOXO3 regulation of ROS in stem cells [15–17,41,42] is mediated in part by transcriptional regulation of several antioxidant enzymes [34] (and reviewed in [33,69]). In addition, FOXO3 regulates NADPH generation and glutathione biosynthesis [63,68]. Here, we found that in addition to the control of oxidative stress, FOXO3 regulates HSC mitochondrial metabolism (Figs 1–4). Our findings suggest that while increased ROS are implicated in enhanced generation of Foxo3- [41] or Foxo-deficient [59] multipotent colony-forming unit-spleen (CFU-S), and cell cycle-related abnormalities of HSPC [14,16,59], elevated ROS do not mediate the functional defects of Foxo3−/− long-term HSC but rather might reflect an abnormal mitochondrial function. These results are consistent with the notion that NAC treatment only partially rescued the p38 MAPK activation in Foxo3−/− HSPC [15]. These findings raise the interesting possibility that underlying mechanisms that uncouple ROS from mitochondrial potential might disengage HSC cycling from HSC repopulation potential.

The outcome of FOXO3 regulation of mitochondria may be context dependent [70–72]. Furthermore, FOXO3 appears to have relatively distinct metabolic functions in neural [68] versus hematopoietic stem cells (current study). Given that loss of quiescence in Foxo3−/− HSC is paradoxically associated with increased glycolysis, these results raise questions regarding FOXO3 regulation of additional metabolic pathways including the pentose phosphate pathway in HSC. These findings together with the regulation of autophagy in aged and stressed HSC [73] underline critical and diverse FOXO3 metabolic functions in stem and progenitor cells.

Inhibition of mTOR signaling rescues the phenotype of the less primitive subset of Foxo3−/− HSPC

mTOR signaling is one of the major signaling pathways implicated in the regulation of mitochondrial metabolism and oxygen...
consumption in somatic and embryonic stem cells [20,65,74,75]. However, the activation of mTOR signaling in Foxo3−/− HSPC seems to mediate the defects of Foxo3−/− ST-HSC, but not LT-HSC. Rapamycin treatment rescued the numbers of Foxo3−/− LSK cells and normalized the mitochondrial membrane potential and ROS in Foxo3−/− LSK cells (Fig 5). In addition, rapamycin rescued the competitive repopulation ability of Foxo3−/− HSC up to 8 weeks, suggesting that mTOR mediates the Foxo3−/− ST-HSC defects (Fig 6). In contrast, while this 2-week period of treatment was clearly sufficient to reduce pS6 downstream of mTOR signaling and rescue Tsc1 and Lkb1 mutant LT-HSC numbers [20,22–24], rapamycin did not rescue the number of Foxo3−/− LT-HSC in treated mice or their competitive repopulating potential in lethally irradiated transplanted hosts (Figs 5 and 6). These findings combined with our previous results [41] indicate that mTOR activation mediates defects of Foxo3−/− myeloid and multipotential progenitors, but not Foxo3−/− LT-HSC abnormalities. These results were not too surprising after all as the phenotype of Foxo3−/− and Tsc1−/− LT-HSC in which mTOR is constitutively activated is quite distinct [20]. Consistent with PTEN-independent regulation of FOXO3 in HSC [48,76], these results (Figs 5 and 6) further delineate differences of mTOR activation in HSC on a background of PTEN versus FOXO3 loss of function [76]. In addition, they suggest that mTOR activation in Foxo3−/− ST-HSC might result in their defective function leading to proliferation of downstream hematopoietic progenitors [41]. As both rapamycin and NAC treatments normalized ROS but not the competitive repopulation of Foxo3−/− LT-HSC, our results support the notion that elevated ROS do not mediate the defective competitive repopulation of Foxo3−/− LT-HSC. However, despite similarities of Foxo3−/− and Foxo3−/− HSC [15–17,41,59], our results do not rule out the potential oxidative stress mediation of in vivo Foxo3−/− HSC competitive repopulation defects [59].

Overall, our results identify FOXO3 as essential for HSC mitochondrial metabolism. They also support a model in which mitochondria is key to the maintenance of LT-HSC (Fig 7). In addition, these findings provide a platform for elucidating FOXO3 metabolic contributions to HSC aging and leukemic stem cell maintenance [45,47].

**Materials and Methods**

**Mice**

Foxo3−/− mice were backcrossed 10 generations onto C57BL6 (CD45.1) background [16]. Mice were used according to the protocols approved by the Institutional Animal Care and Use Committee of Icahn School of Medicine at Mount Sinai.

**Flow cytometry**

Antibody staining and flow cytometry analysis were performed as previously described [16,41]. For Lin−Sca-1−c-Kit+ (c-Kit+) and Lin−Sca-1+c-Kit− (LSK) cells, freshly isolated bone marrow cells were pre-incubated with 5% rat serum and biotinylated hematopoietic multilineage monoclonal antibody cocktail (StemCell Technologies), containing CD5 (lymphocytes), CD11b (leukocytes), CD19 (B cells), CD45R (lymphocytes), 7-4 (neutrophils), Ly-6G-Gr-1 (granulocytes), TER119 (erythroid cells) antibodies to remove mature cells, stained with PE-Sca-1 and APC-c-Kit antibodies (BD Biosciences) prior to two rounds of wash followed by incubation with Pacific Blue–streptavidin. In addition to LSK staining, total bone marrow cells were stained with FITC-CD48 (eBioscience) and PE-Cy7-CD150 (BioLegend) antibodies to isolate the long-term HSC (LSKCD48−CD150−). The MitoTracker and JC-1 probes were used in combination with the lineages antibody cocktail—Pacific Blue–streptavidin, APC-c-Kit, V500-Sca-1, APCy7-CD48 (BD Biosciences) and PE-Cy7-CD150 antibodies. The DilC1(5) probe was used in combination with the lineages antibody cocktail—Pacific Blue–streptavidin, PE-c-Kit (eBioscience), V500-Sca-1, FITC-CD48, and PE-Cy7-CD150 antibodies.

To sub-fractionate the long-term HSC (LSKCD34−Flk2−), bone marrow cells were stained as described [7]. The frequencies and numbers of HSC in the BM are measured per femur and per tibia. Freshly isolated bone marrow cells stained with LSK were fixed with fix/permeabilization buffer (BD Biosciences) and incubated with 1:100 dilution of anti-pSer235/236 S6 antibody (Cell Signaling Technology) followed by incubation with 1:800 dilution of PE-conjugated secondary antibody (BD Biosciences) to measure intracellular phosphorylated S6 (pS6). Samples were washed, and protein phosphorylation was analyzed by flow cytometry.

**Long-term repopulation assay**

Lethally irradiated (12 Gy as a split dose, 6.5 and 5.5 Gy, 4–5 h apart) [16] congenic C57BL6–CD45.1 mice (NCI) were reconstituted with intravenous injections of 100 donor LSKCD48−CD150− cells from C57BL6 mice (CD45.1) along with 2 × 105 competitor bone marrow cells (CD45.2). Reconstitution of donor-derived cells was distinguished from host cells by the expression of CD45.1 versus CD45.2 antigens (BD Biosciences) in the peripheral blood.

**Cell cycle analysis**

To measure the fraction of quiescent cells, bone marrow cells were stained for LSK, fixed, permeabilized, and incubated with Ki-67 antibody (BD Pharmingen) and DAPI to determine the G0 state (1 µg/ml). Samples were immediately analyzed by flow cytometry.
NAC treatment

WT and Foxo3\(^{-/-}\) mice were injected intraperitoneally with 100 mg/kg body weight of N-acetyl-L-cysteine (NAC; Sigma, MO) in phosphate-buffered saline (PBS) solution (pH 7.4) daily, as previously described [16,41]. For long-term treatment, NAC was alternatively injected every day and added to the water every other week.

Rapamycin treatment

WT and Foxo3\(^{-/-}\) mice were injected intraperitoneally with 4 mg/kg body weight of rapamycin (Enzo Life Sciences, NY) in PBS with 5% Tween-80, 5% PEG400 and 4% ethanol during five consecutive days/week for 2 weeks, as previously described [41].

Measurement of intracellular ROS

ROS was measured using CM-H2DCFDA (Molecular Probes) as previously described [16,41]. To measure the concentration of superoxide anion, 10\(^6\) cells stained first for LSK were resuspended in PBS 2% FBS, loaded with 5 \(\mu\)M mitoSOX Red (M36008; Molecular Probes) and incubated in the dark for 30 min at 37°C. The fluorescent product was measured immediately by flow cytometry.

Measurement of mitochondrial mass and membrane potential

To measure the mitochondrial mass, 3 \(\times 10^6\) cells stained first to gate c-Kit\(^+\), LSK, LT-HSC were resuspended in PBS 2% FBS and loaded with 20 nM MitoTracker Green (M7514; Molecular Probes) or 25 nM DilC1(5) (M34151; Molecular Probes) and incubated in the dark for 20 min or 25 min, respectively, at 37°C. For each probe, the fluorescent product was measured immediately by flow cytometry.

Metabolic assays

Oxygen consumption was measured with the BD Oxygen Biosensor System in accordance with the manufacturer’s recommendations, as previously described [7]. ATP levels were quantified with ATP Bioluminescence Assay Kit HS II (Roche) in accordance with the manufacturer’s recommendations, as previously described [7]. Lactate production was measured with gas chromatography–mass spectrometry, as previously described [7].

Protein oxidation detection

Cell lysate proteins were treated as previously described [39], reacted with 2,4-dinitrophenylhydrazine to derivatize carbonyl groups (OxyBlot Protein Oxidation Detection Kit; Chemicon International) to dinitrophenylhydrazone (DNPH) and resolved by 12% SDS–PAGE and detected by rabbit anti-DNPH antibody.

Real-time quantitative RT–PCR

Total RNA was isolated using RNeasy MicroPlus kit (Qiagen). First-strand cDNA was synthesized using SuperScriptIII (Invitrogen). cDNA obtained from 300 cells was used per well for RT–PCR performed using SYBR Green JumpStart Taq ReadyMix (Takara) in triplicates, using the primers indicated in the figures and ABI Prism 7900 HT Cycler (Applied Biosystems, see Primer sequences in Appendix Table S1). All the results were normalized to \(\beta\)-actin RNA levels.

Statistical analysis

Unpaired two-tailed Student’s t-test was used for all experiments. \(P\)-value < 0.05 was considered significant.

References


differentiation and teratoma formation capacity in mouse embryonic stem cells. *J Biol Chem* 283: 28506–28512


76. Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS, Gilliland DC, Morrison SJ (2010) mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. *Cell Stem Cell* 7: 593–605